Aayush Rai, CEO and Co-founder, Inito informs that their AI-based platfrom supports fertility testing and understands cycle variations of every user to give highly accurate results, in an interaction with Prabhat Prakash
How does Inito plan on scaling up its existing platform?
Inito’s flagship innovation enables smartphones to perform lab-grade fertility diagnostic tests at home. Right now, our monitor measures two fertility hormones, estrogen and Luteinising hormone (LH), in urine and enables women to track their fertile days at home and increases their chances of getting pregnant by 89 per cent. Our AI-based app understands cycle variations for every individual user and gives highly accurate results unique to every woman’s body.
We now plan to add eight more hormone tests to the device. This will allow the app to predict several key metrics of fertility for users and diagnose fertility conditions without going to the lab. The data set of hormones collected through 100,000 plus tests taken on the device till now is arguably the largest cloud based dataset of fertility hormones in the world. Using big data analytics and artificial intelligence, Inito will be able to make more accurate predictions about fertility for its future users.
How has Inito disrupted the healthcare sector so far?
According to studies, one in every two couples track their ovulation cycle wrong. Before Inito, the only way around this problem was visiting the labs for regular check-ups. However Inito has brought the accuracy of lab grade tests to the comfort of homes. Additionally, Inito’s data analytics and AI layer also gives personalised results specific to each woman’s body. In many cases, it has also alerted users about complications they were not aware of and suggests going to a doctor if need be. Inito now plans to add eight more hormone tests to the device, this coupled with the dataset of hormones, will enable it to make more accurate predictions about fertility for its future users.
Is Inito looking at other areas of diagnosis?
Inito will continue to double down on fertility in the next 12 months, add eight more fertility hormone testing and then move on to other areas of diagnosis.
How does Inito plan on achieving their goal of a diagnostic lab in every home?
Right now, Inito’s platform supports fertility testing and soon we will be adding eight more hormone tests which will enable women to test for other fertility issues including ovulatory cycles, PCOS etc. on the device. Once we have successfully launched the eight new fertility hormone tests, we will expand to other areas of diagnosis to support our goal of a diagnostic lab in every home.
Inito had plans of launching tests for diabetes, thyroid and vitamin D. What is the progress on that?
When we launched Inito, our plan was to move to other lifestyle related diseases testing after ovulation tests. However, as data started coming in, we soon realised that India was going through an infertility epidemic. This was also evident in the numbers. According to reports, the global fertility services market is expected to rise from its initial estimated value of $ 20,398.07 million in 2018 to an estimated value of $ 41,396.21 million by 2026 registering a CAGR of 9.25 per cent in the forecast period of 2019-2026. This is when we decided to double down on fertility in the next 12 months. What also influenced our decision was the fact that we had gathered the largest dataset of fertility hormones in the world. This put us in a unique situation giving us the capability to solve for the infertility epidemic of India.
Inito had plans on achieving 10x sales in the last financial year. Has that been achieved?
Yes, we grew 10x in revenue between March 2018-2019
Last year Inito raised $1.8 million. How have those funds been utilised? This year Inito has raised funds again. How does Inito plan on utilising it?
The funds raised last year were utilised to improve our product, setup ISO approved manufacturing and production and collect more fertility hormone data. For now, we have sufficient funds thus our focus has shifted to product and growth rather than fundraising.
- Advertisement -